Detailed information for compound 935599

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 457.438 | Formula: C24H19N5O5
  • H donors: 4 H acceptors: 5 LogP: 1.57 Rotable bonds: 8
    Rule of 5 violations (Lipinski): 1
  • SMILES: COc1ccc(cc1c1c[nH]c(=O)[nH]c1=O)C(=O)Nc1ccc(cc1)NC(=O)c1ccccn1
  • InChi: 1S/C24H19N5O5/c1-34-20-10-5-14(12-17(20)18-13-26-24(33)29-22(18)31)21(30)27-15-6-8-16(9-7-15)28-23(32)19-4-2-3-11-25-19/h2-13H,1H3,(H,27,30)(H,28,32)(H2,26,29,31,33)
  • InChiKey: VSFRKGLZMYMIBU-UHFFFAOYSA-N  

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

No curated genes were found associated with this compound

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Giardia lamblia Rrm3p helicase 0.0088 0.5 0.5
Echinococcus multilocularis ATP dependent DNA helicase PIF1 0.0088 0.5 0.5
Entamoeba histolytica DNA repair and recombination protein, putative 0.0088 0.5 0.5
Trypanosoma cruzi DNA repair and recombination helicase protein PIF6, putative 0.0088 0.5 0.5
Trypanosoma cruzi DNA repair and recombination helicase protein PIF7, putative 0.0088 0.5 0.5
Leishmania major PIF1 helicase-like protein, putative,DNA repair and recombination protein, mitochondrial precursor, putative 0.0088 0.5 0.5
Entamoeba histolytica hypothetical protein, conserved 0.0088 0.5 0.5
Leishmania major PIF1 helicase-like protein, putative,DNA repair and recombination protein, mitochondrial precursor, putative 0.0088 0.5 0.5
Trypanosoma brucei DNA repair and recombination helicase protein PIF6 0.0088 0.5 0.5
Trypanosoma brucei DNA repair and recombination helicase protein PIF7 0.0088 0.5 0.5
Trypanosoma cruzi DNA repair and recombination helicase protein PIF7, putative 0.0088 0.5 0.5
Schistosoma mansoni hypothetical protein 0.0088 0.5 0.5
Trichomonas vaginalis conserved hypothetical protein 0.0088 0.5 0.5

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) > 22 uM Inhibition of Escherichia coli ATCC 27325 GlmU expressed in Escherichia coli HMS174(DE3) incubated for 15 mins prior to MgCl2 addition measured after 30 mins by malachite green staining-based assay ChEMBL. 25262942
IC50 (binding) > 30 uM Inhibition of human AURKB incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay ChEMBL. 25262942
IC50 (binding) > 30 uM Inhibition of human IRAK4 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay ChEMBL. 25262942
IC50 (binding) > 30 uM Inhibition of human IRAK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay ChEMBL. 25262942
IC50 (binding) > 30 uM Inhibition of human JAK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay ChEMBL. 25262942
IC50 (binding) > 30 uM Inhibition of human JAK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay ChEMBL. 25262942
IC50 (binding) > 30 uM Inhibition of human JAK3 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay ChEMBL. 25262942
IC50 (binding) > 30 uM Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay ChEMBL. 25262942
IC50 (binding) > 30 uM Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay ChEMBL. 25262942
IC50 (binding) > 30 uM Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay ChEMBL. 25262942
PB (ADMET) > 99 % Serum protein binding in human at 10 uM after 30 mins by ultrafiltration method ChEMBL. 25262942

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.